CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
430.50MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.50xvs all stocks
52-Week Change
26.97%vs all stocks
Market Capitalization
430.50MUSDvs all stocks (USD)
Enterprise Value
321.77MUSDvs all stocks (USD)
Forward P/E
-7.32xvs Biotechnology peers
Price to Book (MRQ)
3.77xvs Biotechnology peers
Enterprise to EBITDA
-6.84xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-33.84%vs Biotechnology peers
Return on Equity (TTM)
-54.52%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-47.07MUSDvs all stocks (USD)
Net Income (TTM)
-46.98MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-32.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-17.57MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-1.60MUSDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-38.43MUSDvs all stocks (USD)
Pre-tax Income
-38.59MUSDFY2025 · Dec 31, 2025Income Tax Expense
19.09KUSDFY2025 · Dec 31, 2025Net Income
-38.61MUSDFY2025 · Dec 31, 2025EBIT
-38.59MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-36.78MUSDFY2025 · Dec 31, 2025Research & Development
21.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
17.10MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.41MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-1.03USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.03USDFY2025 · Dec 31, 2025Basic Shares Outstanding
39.96MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
39.96MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-38.61MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
29.51KUSDFY2025 · Dec 31, 2025Operating Cash Flow
-27.48MUSDFY2025 · Dec 31, 2025Free Cash Flow
-28.07MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
80.56MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-38.61MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
237.72KUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.04MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-76.94KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-431.45KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.36MUSDFY2025 · Dec 31, 2025Capital Expenditures
-588.95KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-588.95KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
73.89MUSDFY2025 · Dec 31, 2025Shares Outstanding
61.81MSharesUpdated Jul 18, 2026Float Shares
51.20MSharesUpdated Jul 18, 2026Shares Short
4.60MSharesUpdated Jul 18, 2026Short Ratio
12.38daysvs all stocks
% Held by Insiders
14.22%vs all stocks
% Held by Institutions
41.96%vs all stocks
Total Cash (MRQ)
138.88MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.13USDUpdated Jul 18, 2026Total Debt (MRQ)
2.01MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0147xvs Biotechnology peers
Current Ratio (MRQ)
19.30xvs Biotechnology peers
Book Value per Share (MRQ)
1.75USDUpdated Jul 18, 2026Total Assets
86.15MUSDvs all stocks (USD)
Total Current Assets
85.10MUSDFY2025 · Dec 31, 2025Total Liabilities
5.70MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.05MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
75.91KUSDFY2025 · Dec 31, 2025Total Current Liabilities
5.63MUSDFY2025 · Dec 31, 2025Cash
80.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
80.56MUSDFY2025 · Dec 31, 2025Short-term Debt
78.45KUSDFY2025 · Dec 31, 2025Long-term Debt
75.91KUSDFY2025 · Dec 31, 2025Common Stock (Book)
195.41MUSDFY2025 · Dec 31, 2025Retained Earnings
-169.58MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
80.45MUSDvs all stocks (USD)
52-Week Low
4.88USDUpdated Jul 18, 202652-Week High
9.32USDUpdated Jul 18, 202652-Week Change
26.97%vs all stocks
Beta
1.50xvs all stocks
50-Day MA
6.67USDUpdated Jul 18, 2026200-Day MA
6.99USDUpdated Jul 18, 2026Avg 10-Day Volume
199.24KSharesUpdated Jul 18, 2026Avg 30-Day Volume
367.72KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.05USDUpdated Jul 18, 2026Other Income / Expense
-1.57MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.57
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Canopy Growth Corporation
Tier 1ProductionApproval-Gated PipelineFlowRule
Puma Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Jiaoda Onlly Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gujarat Themis Biosyn Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Evommune, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Jiangsu Hengli Hydraulic Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Halo Microelectronics Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets